Novel Surrogate Markers of Angiogenesis for Clinical Trials Herbert I. Hurwitz, M.D., Duke University Medical Center. Searches are being made for surrogate markers. One approach that is being investigated at Duke involves wound healing. The rate of healing of a small superficial wound can be correlated with the effectiveness of the anti-cancer therapy. Farnesyl Tranferase Inhibitors Paul Kirschenmeier, Ph.D., Schering Plough.
Localization is essential for the oncoprotein to be active.
FPTs should be excellent targets for cancer therapy. The side effects associated with its use are diarrhea and nausea. It does not bind to zinc. Not all human tumor cell lines respond to FTIs. These mutants undergo geranylgeranylation in the presence of FTIs, which bypasses the farnesylation blockade.